samedan logo

 
 
spacer
home > pmps > summer 2007 > a breath of fresh air
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Breath of Fresh Air

Tim Sandle at Bio Products Laboratory evaluates the validation of active air-sampling

Environmental monitoring is a programme which evaluates the cleanliness of the manufacturing environment; the effectiveness of cleaning and disinfection programmes; and the operational performance of environmental controls. As such, pharmaceutical manufacturers of both sterile and non-sterile products, as well as medical devices, are required to demonstrate that manufacturing processes and procedures minimise any potential contamination to the product from the manufacturing environment. Contamination can arise from a number of sources: water, air, surfaces and personnel, each of which poses a potential risk to product.

Each microbiological environmental monitoring method requires validation in order to show its suitability within the cleanroom environment. Due to the importance placed on environmental monitoring data, the results which the manufacturer obtains must be reproducible and assure that the aseptic environment or trends within non-sterile manufacturing are under control. Arguably, now more than ever, environmental data is scrutinised during FDA CGMP and pre-approval new drug inspections – this trend is likely to continue. This reproducibility can be established through method validation.

Although standard environmental test methods have been in existence for years and are accepted throughout the industry, they do not necessarily yield reproducible results. One type of culture media used in conjunction with one type of air-sampler in a particular facility will behave very differently to another. In addition, new test methodologies must be validated to be as good as, or better, than the methods they are replacing. This makes at least some validation of monitoring methods essential.

This article examines the validation of one aspect of microbiological monitoring: active air-sampling. Air-sampling is important as the air in most manufacturing areas is microbiologically contaminated, although the level will vary: an office will be considerably more contaminated when compared to a Grade B cleanroom. Whilst air is a vector of micro-organisms, it is not a nutritive environment. Therefore, many micro-organisms in the air die from desiccation or photosensitivity. Many other micro-organisms are anaerobic and thus will not survive or will be unable to multiply. However, microorganisms may be able to settle onto critical surfaces. As much of the risk centres on air velocities and air flows, the use of active volumetric air-samplers is important.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.

spacer
Tim Sandle is the company Microbiologist at Bio Products Laboratory (BPL), the manufacturing unit of the National Blood Authority, a special health authority within the NHS. Prior to his current role, Tim has worked on a number of different microbiological projects within the pharmaceutical industry, including: developments in the testing of endotoxins and pyrogens for protein-based products; establishing the environmental monitoring regime for a network of over 200 cleanrooms; and validating a sterility testing isolator system. Tim has written more than 30 articles relating to microbiology and pharmaceutical operations, including LAL testing, operation of isolators, cleanrooms and environmental monitoring.
spacer
Tim Sandle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

BURLINGAME, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, in partnership with Merck, today announced the first patient has been dosed in the Phase 2 ASPEN-03 study.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

A Magic Triangle: Practical insights into lactose-based DPI formulations

30 June 2021, Online webinar

Three leading companies with complementary areas of expertise have joined forces to conduct a unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate. Their findings will give generic players a head start in the development process so that they can tap into this rapidly growing market. Lactose specialist DFE Pharma, powder processing technology manufacturer Hosokawa Micron and machine-building expert Harro Hoefliger will be presenting the key insights from their research to interested parties during a joint webinar on the 30th of June.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement